Data may be made available upon request due to ethical restrictions imposed by the Swiss IBD cohort study group which collected this data. Interested researchers may request access to the collected data from this study in the same manner as the authors did. Data is available upon ethical approval and a request to the Head of the cohort, Dr. Phil Gerhard Rogler, at <gerhard.rogler@usz.ch>. Data access requests may also be made to the Swiss IBD Cohort at <sibdcs-submission@chuv.ch> or <http://ibdcohort.ch/index.php/informationen-fuer-forscher.html>.

Introduction {#sec005}
============

Pain is a common symptom in patients with inflammatory bowel disease (IBD) \[[@pone.0215738.ref001], [@pone.0215738.ref002]\]. In a recent study we showed that the vast majority of patients (71%) within the Swiss IBD Cohort Study experienced pain during their disease course and that for 52% of the patients pain was a longstanding problem \[[@pone.0215738.ref003]\]. Abdominal pain can be a direct or indirect consequence of intestinal inflammation; however, extraintestinal manifestations (EIM) of IBD can also cause pain and pain in itself can be seen as an EIM \[[@pone.0215738.ref004]--[@pone.0215738.ref006]\]. The most common EIM of IBD are arthropathies \[[@pone.0215738.ref005], [@pone.0215738.ref007]--[@pone.0215738.ref017]\]. Also, in our former study we could show that pain has a substantial impact on health-related quality of life (HRQOL) of IBD patients, as the general quality of life was significantly lower in patients suffering from pain compared to those without pain \[[@pone.0215738.ref003]\]. Such a relationship has also been described in other chronic diseases \[[@pone.0215738.ref018]--[@pone.0215738.ref021]\].

Treatment of both, IBD and IBD associated pain is challenging. The mainstay of IBD treatment includes systemic immunosuppressive medications, such as corticosteroids, anti-tumor necrosis factor (TNF) antibodies or immunomodulators. Furthermore, the management of an acute flare differs from the strategies for maintenance of remission \[[@pone.0215738.ref022], [@pone.0215738.ref023]\]. Moreover, presence of EIM will also influence the choice of a treatment regime. For instance, anti-TNF therapy is known to be very effective regarding gut inflammation as well as arthropathies/ arthritis.

Furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) can very effectively mediate pain relieve due to their analgetic and also anti-inflammatory effects. However, due to the risk of disease exacerbation and induction of flares their use in IBD is limited \[[@pone.0215738.ref024]--[@pone.0215738.ref030]\].

Here, we used the well-characterized patient collective of the Swiss IBD Cohort Study (SIBDCS) to study the association of pain and IBD treatment with a focus on anti-TNF treatment.

Methods {#sec006}
=======

Ethics consideration {#sec007}
--------------------

Ethics approval was obtained from the regional Swiss Ethics Committees in which cohort participants were enrolled (Commission d'éthique du Canton de Vaud, Lausanne, Switzerland/Protocol no. 33/06). Written, informed consent was obtained from each patient included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution\'s human research committee.

Study design {#sec008}
------------

Patients of the nationwide SIBDCS have been prospectively included since 2006 with a yearly follow-up. The cohort goals und methodology of SIBDC have been described elsewhere\[[@pone.0215738.ref031]\].

A questionnaire addressing various aspects of pain including pain duration localization and frequency was mailed to 2152 SIBDC patients, representing the entire cohort. The questionnaire also inquired about the use of pain specific medication in detail. Our questionnaire contained several questions from a validated German pain questionnaire \[[@pone.0215738.ref032]\]. The questionnaire was used in a German and in a French version. Further details of the questionnaires including the fully originally used French and German versions are described elsewhere \[[@pone.0215738.ref003]\]. Basic epidemiological and clinical data including the use of IBD specific therapy was retrieved from the SIBDCS databases. All data are stored in Microsoft Access (Microsoft Corporation) databases.

Statistical analysis {#sec009}
--------------------

Descriptive statistical analyses were performed: Categorical variables were summarized as frequencies and percentages, whereas quantitative variables as median and range. To assess differences in categorical data distribution between groups of different sizes, Fisher's exact test was used.

The statistical analysis was performed using GraphPad Prism 7 for MacOS. A p-value of \<0.05 was considered statistically significant.

Results {#sec010}
=======

Patient's characteristics {#sec011}
-------------------------

The patients' characteristics shown in [Table 1](#pone.0215738.t001){ref-type="table"} have been described previously \[[@pone.0215738.ref003]\]. In brief: 1263 out of 2152 patients completed the questionnaires (response rate 59%). 599 out of 1263 patients were male (47%) and 664 female (53%). The median age was 47 years. Extraintestinal manifestations (EIM) of IBD were present in 699 patients (55%). The median IBD disease duration was 15 years (mean: 15 years, range: 0--57 years). The vast majority of patients (894/ 1263, 71%) reported the experience of pain in general during the course of the disease. [Table 2](#pone.0215738.t002){ref-type="table"} shows the frequency of IBD specific treatment.

10.1371/journal.pone.0215738.t001

###### Patient characteristics.

![](pone.0215738.t001){#pone.0215738.t001g}

  Patient characteristics        Number of patients (%)   
  ------------------------------ ------------------------ ----------
  **Gender**                     **Female**               664 (53)
  **Male**                       599 (47)                 
  **Diagnosis**                  **CD**                   679 (54)
  **UC**                         556 (44)                 
  **IC**                         28 (2)                   
  **Sum**                        1263 (100)               
  **Pain**                       **Yes**                  894 (71)
  **No**                         369 (29)                 
  **EIM**                        **Yes**                  699 (55)
  **No**                         564 (45)                 
  **Disease duration (Years)**   **Average**              15
  **Min-Max**                    0--57                    

10.1371/journal.pone.0215738.t002

###### IBD specific treatment.

![](pone.0215738.t002){#pone.0215738.t002g}

  --------------------------------------------------------------------------
  IBD treatment                       Number of patients (%)\   
                                      with pain without pain    
  ----------------------------------- ------------------------- ------------
  **Anti-TNF**                        216 (24.2)                100 (27.1)

  **Steroids**                        198 (22.1)                73 (19.8)

  **5-aminosalicylic acid (5-ASA)**   334 (37.4)                136 (36.9)

  **Antibiotics**                     11 (1.2)                  6 (1.6)

  **Calcineurin-Inhibitors**          12 (1.3)                  5 (1.4)

  **Immunomodulators**                316 (35.3)                125(33.9)
  --------------------------------------------------------------------------

Association between IBD specific treatment and pain localization {#sec012}
----------------------------------------------------------------

When comparing the use of IBD specific medication and ten different pain localizations, we found several significant differences. Regarding elbow pain, only 21 patients (10%) receiving anti-TNF treatment compared to 142 patients (21%) not receiving anti-TNF were affected (p = 0.002). Other pain localizations did not reveal significant differences regarding anti-TNF treatment ([Table 3](#pone.0215738.t003){ref-type="table"}).

10.1371/journal.pone.0215738.t003

###### Pain localization.

![](pone.0215738.t003){#pone.0215738.t003g}

                       Anti-TNF     No anti-TNF   
  -------------------- ------------ ------------- -----------
  **Head**             56 (26)      147 (21.7)    0.193
  **Neck**             28 (13)      95 (14)       0.735
  **Finger/hand**      53 (24.5)    142 (20.9)    0.297
  **Elbow**            21 (9.7)     142 (20.9)    **0.002**
  **Shoulder**         44 (20.4)    138 (20.4)    \>0.999
  **Back**             77 (35.6)    236 (34.8)    0.869
  **Hip/thigh**        52 (24)      162 (23.9)    \>0.999
  **Knee/lower leg**   61 (28.2)    181 (26.7)    0.660
  **Ankle/foot**       35 (16.2)    109 (16.1)    \>0.999
  **Abdomen**          105 (48.6)   375 (55.3)    0.099

Comparing other IBD specific therapy and the different pain localization, we found patients not receiving steroid treatment significantly less often to be suffering from elbow pain compared to patients receiving steroids (8% vs. 14%; p = 0.021). For the evaluation of other pain localizations and other IBD specific therapy (5-ASA, calcineurin-inhibitors, immunomodulators) no significant differences were observed ([S1](#pone.0215738.s001){ref-type="supplementary-material"}--[S5](#pone.0215738.s005){ref-type="supplementary-material"} Tables).

Association between IBD specific treatment and duration of pain {#sec013}
---------------------------------------------------------------

Duration of pain did not differ between patients on anti-TNF treatment versus those not on anti-TNF treatment ([Table 4](#pone.0215738.t004){ref-type="table"}). The duration of pain was also not influenced by other IBD specific medications (Steroids, 5-ASA, Antibiotics, Calcineurin-inhibitors, Immunomudulators) also, no significant differences were observed ([S6](#pone.0215738.s006){ref-type="supplementary-material"}--[S10](#pone.0215738.s010){ref-type="supplementary-material"} Tables).

10.1371/journal.pone.0215738.t004

###### Duration of pain.

![](pone.0215738.t004){#pone.0215738.t004g}

                       Anti-TNF    No anti-TNF   
  -------------------- ----------- ------------- -------
  **\<1 month**        6 (2.7)     9 (1.3)       0.218
  **1 month-½ year**   20 (9.3)    37 (5.5)      0.054
  **½ year-1 year**    13 (6)      46 (6.8)      0.608
  **1--2 years**       18 (8.3)    61 (9)        0.890
  **2--5 years**       51 (23.6)   164 (24.2)    0.927
  **\>5 years**        108 (50)    361 (53.2)    0.434

Association between IBD specific treatment and frequency of pain {#sec014}
----------------------------------------------------------------

The frequency of pain in patients with and without anti-TNF treatment did not significantly differ ([Table 5](#pone.0215738.t005){ref-type="table"}). When comparing the pain frequencies of patients taking other IBD specific medications (steroids, 5-ASA, antibiotics, calcineurin-inhibitors, immunomodulators), also no significant differences were observed ([S11](#pone.0215738.s011){ref-type="supplementary-material"}--[S15](#pone.0215738.s015){ref-type="supplementary-material"} Tables).

10.1371/journal.pone.0215738.t005

###### Frequency of pain.

![](pone.0215738.t005){#pone.0215738.t005g}

                                Anti-TNF    No anti-TNF   
  ----------------------------- ----------- ------------- ---------
  **Several times daily**       49 (28.2)   115 (22)      0.099
  **1x/day**                    11 (6.3)    34 (6.5)      \>0.999
  **Several times per week**    34 (19.5)   100 (19.1)    0.911
  **1x/week**                   11 (6.3)    26 (5)        0.557
  **Several times per month**   28 (16.1)   102 (19.5)    0.369
  **1x/month**                  12 (6.9)    55 (10.5)     0.182
  **\<1x/month**                29 (16.7)   91 (17.4)     0.907

Association between IBD specific treatment and pain character {#sec015}
-------------------------------------------------------------

Further, there was no association between the pain character and the use of IBD specific medication. 36 patients (20%) on anti-TNF treatment described their pain to be constant with slight fluctuations compared to 115 patients (19%) without anti-TNF treatment (p\>0.999). Constant pain with strong fluctuations was reported by 15 patients (8%) using anti-TNF treatment and by 64 patients (11%) not receiving anti-TNF treatment (p = 0.331). 115 patients (61%) with TNF treatment and 349 (58%) without anti-TNF treatment experienced pain attacks with pain free intervals (p = 0.554). Pain attacks with constant pain were reported by 30 patients (16%) receiving anti-TNF treatment compared to 75 (12%) not receiving anti-TNF (p = 0.268). When comparing the pain character of patients receiving other IBD specific medication (steroids, 5-ASA, antibiotics, calcineurin-inhibitors, immunomodulators), no significant differences across treatment groups were seen ([S16](#pone.0215738.s016){ref-type="supplementary-material"}--[S21](#pone.0215738.s021){ref-type="supplementary-material"} Tables).

Association between IBD specific treatment and duration of pain attacks {#sec016}
-----------------------------------------------------------------------

Moreover, the duration of pain attacks was not influenced by IBD specific medication ([Table 6](#pone.0215738.t006){ref-type="table"}), neither with regards to anti-TNF nor other agents to treat IBD, including steroids, 5-ASA, Antibiotics, Calcineurin-Inhibitors, Immunmodulators ([S22](#pone.0215738.s022){ref-type="supplementary-material"}--[S26](#pone.0215738.s026){ref-type="supplementary-material"} Tables).

10.1371/journal.pone.0215738.t006

###### Duration of pain attacks.

![](pone.0215738.t006){#pone.0215738.t006g}

                 Anti-TNF    No anti-TNF   
  -------------- ----------- ------------- -------
  **Seconds**    26 (14.9)   61 (11.9)     0.295
  **Minutes**    56 (32)     158 (30.8)    0.777
  **Hours**      55 (31.4)   175 (34)      0.577
  **\<3 days**   21 (12)     67 (13)       0.793
  **\>5 days**   17 (9.7)    53 (10.3)     0.885

Comparison of pain localization of male and female patients with and without anti-TNF therapy {#sec017}
---------------------------------------------------------------------------------------------

From a total of 894 patients, a similar fraction of male and female patients (24% for both) received anti-TNF therapy ([Fig 1](#pone.0215738.g001){ref-type="fig"}).

![Male and female patients with and without Anti-TNF.](pone.0215738.g001){#pone.0215738.g001}

When comparing the pain localizations of male and female patients receiving anti-TNF treatment significantly fewer male patients with anti-TNF treatment suffered from knee/ lower leg pain compared to female patients receiving anti-TNF therapy (20% vs. 36%; p = 0.015). Also, significantly fewer male patients receiving anti-TNF treatment reported ankle/ foot pain compared to female patients with anti-TNF treatment (10% vs. 22%; p = 0.015). For the other pain localizations, no differences regarding gender were seen ([Table 7](#pone.0215738.t007){ref-type="table"}).

10.1371/journal.pone.0215738.t007

###### Pain localization of male vs. female patients with anti-TNF.

![](pone.0215738.t007){#pone.0215738.t007g}

                       Anti-TNF/ male   Anti-TNF/ female   
  -------------------- ---------------- ------------------ -----------
  **Back**             32 (30.8)        45 (40.2)          0.158
  **Knee/lower leg**   21 (20.2)        40 (35.7)          **0.015**
  **Elbow**            11 (10.6)        10 (8.9)           0.819
  **Hip/thigh**        22 (21.2)        30 (26.8)          0.344
  **Finger/hand**      21 (20.2)        32 (28.6)          0.158
  **Ankle/foot**       10 (9.6)         25 (22.3)          **0.015**

We did not observe any differences in pain localizations in patients with versus without anti-TNF-therapy, neither in male nor female patients (Tables [8](#pone.0215738.t008){ref-type="table"} and [9](#pone.0215738.t009){ref-type="table"}).

10.1371/journal.pone.0215738.t008

###### Pain localization of male patients with vs. without anti-TNF.

![](pone.0215738.t008){#pone.0215738.t008g}

                       Anti-TNF/ male   No anti-TNF/ male   
  -------------------- ---------------- ------------------- -------
  **Back**             32 (30.8)        122 (38)            0.198
  **Knee/lower leg**   21 (20.2)        89 (27.7)           0.156
  **Elbow**            11 (10.6)        28 (8.7)            0.561
  **Hip/thigh**        22 (21.2)        73 (22.7)           0.787
  **Finger/hand**      21 (20.2)        69 (21.5)           0.890
  **Ankle/foot**       10 (9.6)         51 (15.9)           0.146

10.1371/journal.pone.0215738.t009

###### Pain localization of female patients with vs. without anti-TNF.

![](pone.0215738.t009){#pone.0215738.t009g}

                       anti-TNF/female   No anti-TNF/female   
  -------------------- ----------------- -------------------- -------
  **Back**             45 (40.2)         114 (31.9)           0.110
  **Knee/lower leg**   40 (35.7)         92 (25.8)            0.053
  **Elbow**            10 (8.9)          38 (10.6)            0.721
  **Hip/thigh**        30 (26.8)         89 (24.9)            0.709
  **Finger/hand**      32 (28.6)         73 (20.4)            0.090
  **Ankle/foot**       25 (22.3)         58 (16.2)            0.156

Discussion {#sec018}
==========

In our study population 5-aminosalycylicacid (5-ASA) (37%) was the most frequently used IBD specific medication, followed by immunomodulators (35%) and anti-TNF antibodies (24%). As for anti-TNF, Vavricka et al. showed that in more than 40% of the cases, this therapy regime is initiated to treat EIM rather than bowel inflammation and over 70% showed a clinical response of EIM to anti-TNF therapy \[[@pone.0215738.ref006]\]. Our study supports these findings: we could show that significantly less patients on anti-TNF reported elbow pain compared to patients not on anti-TNF. Of note, significantly more patients on steroid treatment reported elbow pain. Refrences to support these findings are lacking.

Regarding gender specific differences in treatment of EIM/ pain in IBD patients, data is not consistent. Concerning IBD treatment, Lopetusa et al. found no general influence of the gender on the therapy of ulcerative colitis (UC) with anti-TNF (infliximab) \[[@pone.0215738.ref033]\]. However, female patients with steroid-refractory UC and successive anti-TNF treatment showed an increased 1-year remission rate and a cumulative non-colectomy rate. In contradiction, Lopetusa et al. found a lower rate of response to treatment and of disease remission in female patients under TNF inhibitors with axial spondyloarthritis\[[@pone.0215738.ref034]\]. As for possible explanations, Nguyen et al. showed that the three biomarkers praealbumin, platelet factor 4 and S100A12 accurately predict the response of patients with rheumatoid arthritis to TNF inhibitors\[[@pone.0215738.ref035]\]. Further studies about a gender-specific correlation of these marker could reveal useful findings. In our study, we found that statistically significant less male patients with anti-TNF treatment reported knee/ lower leg and foot/ ankle pain compared to female patients with anti-TNF. This data may indicate that there is a gender difference regarding the effect of anti-TNF therapy for EIM.

One strength of our study is the size of the cohort with 1263 completed questionnaires. Together with our former study evaluating pain in the SIBDCS \[[@pone.0215738.ref003]\] it is, to the best of our knowledge, the largest evaluation of pain and the use of IBD specific therapy in IBD up to date.

However, our study also has limitations. Due to the study design and the lack of control regarding unreturned questionnaires, a reporting bias cannot be excluded. Patients who actually suffer from pain due to IBD therefore might be overrepresented compared to patients without pain, since the former might be more motivated to return the questionnaire. The patients not responding to the survey might have represented a different phenotype regarding our topic of interest. The existing data of the SIBDCS doesn't include any information about pain, preventing us from compairing pain specific parameters between responders and non-responders. Furthermore, regarding the use of IBD specific therapy and pain localizations, we do not have information on the reason to initiate medical therapy (i.e. EIM vs. intestinal activity of IBD or both) and how high the prevalence of pain has been before treatment initiation. Our statistical evaluation of the data represents another limitation. We have performed a mostly derscriptive analysis of the dataset. To remain a high response rate and not no overstrain the goodwill of the patients, we intended to keep our questionnaire on a simplistic level. We further see the sizes of our subgroups as a potential limitation. We are aware that small subgroups may be linked to random positive findings. In comparison to other studies about pain in IBD, the subgroups examined here are not considerably small. Furthermore, we aimed to include as many pain localizations as possible to thoroughly analyse the distribution of pain. Additionally, our findings, particularly regarding Anti-TNF, match the clinical observations, depicting a genuine outcome.

In summary, we could show that the frequency of elbow pain was lower in patients treated with anti-TNF but higher under steroid treatment. There were no significant differences regarding the use IBD specific therapy and the character, duration and frequency of pain. Furthermore, our data point towards a higher treatment benefit of anti-TNF with regards to EIM in male patients which should be followed up in future studies.
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